Exelixis | EXEL - Le Coût Des Ventes





Le Coût Des Ventes Changement Date
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Agios Pharmaceuticals USD 1.88M 199K 2025-12
Akebia Therapeutics USD 10.34M 441K 2025-12
Amgen USD 1.79B 128M 2025-12
AstraZeneca USD 3.27B 471M 2025-12
Bayer EUR 4.5B 194M 2025-12
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Bristol-Myers Squibb USD 4.92B 657M 2025-12
Cytokinetics USD 99.23M 13.32M 2025-09
Eisai JPY 51.08B 5.56B 2025-12
Eli Lilly USD 3.37B 363.7M 2025-12
Esperion Therapeutics USD 27.85M 13.43M 2025-12
Exelixis USD 26.48M 7.91M 2025-12
Genmab DKK 81M 23M 2025-12
Glaxosmithkline GBP 3.47B 461.37M 2025-12
Incyte USD 121.18M 22.18M 2025-12
Ionis Pharmaceuticals USD 8M 5.66M 2025-12
MacroGenics USD 10.12M 34.18M 2025-12
Merck USD 3.32B 531M 2025-12
Moderna USD 452M 245M 2025-12
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Novartis USD 3.54B 3M 2025-12
Pfizer USD 6.29B 2.12B 2025-12
Puma Biotechnology USD 29.1M 18.44M 2024-09
Sanofi EUR 3.76B 344M 2025-12
Takeda JPY 401.15B 184.07B 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
Xencor USD 61.66M 50.95M 2025-06